Botanix Pharmaceuticals Limited
BXPHF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.05 | -0.04 | -0.33 | -1.35 |
| FCF Yield | -5.84% | -3.26% | -0.95% | -7.32% |
| EV / EBITDA | -15.91 | -28.90 | -46.47 | -85.20 |
| Quality | ||||
| ROIC | -43.92% | -33.20% | -8.12% | -14.31% |
| Gross Margin | 52.64% | -220.09% | -58.08% | -800.40% |
| Cash Conversion Ratio | 0.87 | 0.99 | 0.52 | 0.69 |
| Growth | ||||
| Revenue 3-Year CAGR | 2.82% | -25.66% | -29.35% | -31.91% |
| Free Cash Flow Growth | -57.31% | -589.81% | 76.03% | -123.73% |
| Safety | ||||
| Net Debt / EBITDA | 0.66 | 1.54 | 9.44 | 6.64 |
| Interest Coverage | -10.74 | 0.00 | -1,095.11 | -980.25 |
| Efficiency | ||||
| Inventory Turnover | 0.09 | 0.07 | 2.21 | 1.09 |
| Cash Conversion Cycle | 727.75 | 1,152.34 | -7.65 | 101.15 |